Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1...read more
The longest-ever US government shutdown is finally ending, meaning that the normal path to public markets is set to reopen. While we don’t expect a rush of IPOs due to a backlogged SEC, pressure on AI and other tech stocks, and the approaching holiday...read more
Six IPOs debuted this week, while seven SPACs listed. Eight IPOs submitted initial filings, including a handful of sizable issuers. Five SPACs also submitted initial filings. Dual listing in the US and London, newly-formed REIT Fermi (FRMI) priced its IPO...read more
US IPO Week Ahead: Markets set for a quiet week after year’s first sizable IPO
...read more
US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market
Updated Monday, 1/5. One sizable deal is scheduled for the week ahead, with one smaller deal tentatively scheduled. Solid tumor biotech Aktis Oncology (AKTS) plans to raise $200 million at an $860 million market cap. The company is a Phase 1 ...read more
The US government is finally reopening. Here are the IPOs we could see before the end of 2025.
The longest-ever US government shutdown is finally ending, meaning that the normal path to public markets is set to reopen. While we don’t expect a rush of IPOs due to a backlogged SEC, pressure on AI and other tech stocks, and the approaching holiday...read more
US IPO Weekly Recap: Data infrastructure, flood insurance, and banking debut in 6 IPO week
Six IPOs debuted this week, while seven SPACs listed. Eight IPOs submitted initial filings, including a handful of sizable issuers. Five SPACs also submitted initial filings. Dual listing in the US and London, newly-formed REIT Fermi (FRMI) priced its IPO...read more